Sisi Chen

Sisi Chen

Auto-generated profile, based on publicly available information

Sisi Chen

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SCSisi Chen
Sisi Chen
RVRahul S. Vedula
Rahul S. Vedula
ACAntonio Cuevas-Navarro
Antonio Cuevas-Navarro
BLBin Lu
Bin Lu
SHSimon J. Hogg
Simon J. Hogg
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Recently, screens for mediators of resistance to FLT3 and ABL kinase inhibitors in leukemia resulted in the discovery of LZTR1 as an adapter of a Cullin-3 RING E3 ubiquitin ligase complex responsible for the degradation of RAS GTPases. In parallel, dysregulated LZTR1 expression via aberrant splicing and mutations was identified in clonal hematopoietic conditions. Here we identify that loss of LZTR1, or leukemia-associated mutants in the LZTR1 substrate and RAS GTPase RIT1 that escape degradation, drives hematopoietic stem cell (HSC) expansion and leukemia in vivo. Although RIT1 stabilization was sufficient to drive hematopoietic transformation, transformation mediated by LZTR1 loss required MRAS. Proteolysis targeting chimeras (PROTAC) against RAS or reduction of GTP-loaded RAS overcomes LZTR1 loss-mediated resistance to FLT3 inhibitors. These data reveal proteolysis of noncanonical RAS proteins as novel regulators of HSC self-renewal, define the function of RIT1 and LZTR1 mutations in leukemia, and identify means to overcome drug resistance due to LZTR1 downregulation. Significance: Here we identify that impairing proteolysis of the noncanonical RAS GTPases RIT1 and MRAS via LZTR1 downregulation or leukemia-associated mutations stabilizing RIT1 enhances MAP kinase activation and drives leukemogenesis. Reducing the abundance of GTP-bound KRAS and NRAS overcomes the resistance to FLT3 kinase inhibitors associated with LZTR1 downregulation in leukemia. This article is highlighted in the In This Issue feature, p. 2221

27 September 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
HCHongxia Chen
Hongxia Chen
YBYunpeng Bai
Yunpeng Bai
MKMichihiro Kobayashi
Michihiro Kobayashi
SXShiyu Xiao
Shiyu Xiao
SBSergio Barajas
Sergio Barajas
YLYan Liu
Yan Liu
Receptor tyrosine kinase KIT is frequently activated in acute myeloid leukemia (AML). While high PRL2 (PTP4A2) expression is correlated with activation of SCF/KIT signaling in AML, the underlying mechanisms are not fully understood. We discovered that inhibition of PRL2 significantly reduces the burden of oncogenic KIT-driven leukemia and extends leukemic mice survival. PRL2 enhances oncogenic KIT signaling in leukemia cells, promoting their proliferation and survival. We found that PRL2 dephosphorylates CBL at tyrosine 371 and inhibits its activity toward KIT, leading to decreased KIT ubiquitination and enhanced AKT and ERK signaling in leukemia cells. Implications: Our studies uncover a novel mechanism that fine-tunes oncogenic KIT signaling in leukemia cells and will likely identify PRL2 as a novel therapeutic target in AML with KIT mutations.

4 April 2023
Verified
Other
Open access
SCSisi Chen
Sisi Chen
RVRahul S. Vedula
Rahul S. Vedula
ACAntonio Cuevas-Navarro
Antonio Cuevas-Navarro
BLBin Lu
Bin Lu
SHSimon J. Hogg
Simon J. Hogg
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Recently, screens for mediators of resistance to FLT3 and ABL kinase inhibitors in leukemia resulted in the discovery of LZTR1 as an adapter of a Cullin-3 RING E3 ubiquitin ligase complex responsible for the degradation of RAS GTPases. In parallel, dysregulated LZTR1 expression via aberrant splicing and mutations was identified in clonal hematopoietic conditions. Here we identify that loss of LZTR1, or leukemia-associated mutants in the LZTR1 substrate and RAS GTPase RIT1 that escape degradation, drives hematopoietic stem cell (HSC) expansion and leukemia in vivo. Although RIT1 stabilization was sufficient to drive hematopoietic transformation, transformation mediated by LZTR1 loss required MRAS. Proteolysis targeting chimeras (PROTAC) against RAS or reduction of GTP-loaded RAS overcomes LZTR1 loss-mediated resistance to FLT3 inhibitors. These data reveal proteolysis of noncanonical RAS proteins as novel regulators of HSC self-renewal, define the function of RIT1 and LZTR1 mutations in leukemia, and identify means to overcome drug resistance due to LZTR1 downregulation.Significance:Here we identify that impairing proteolysis of the noncanonical RAS GTPases RIT1 and MRAS via LZTR1 downregulation or leukemia-associated mutations stabilizing RIT1 enhances MAP kinase activation and drives leukemogenesis. Reducing the abundance of GTP-bound KRAS and NRAS overcomes the resistance to FLT3 kinase inhibitors associated with LZTR1 downregulation in leukemia.This article is highlighted in the In This Issue feature, p. 2221

4 April 2023
Verified
Other
Open access
SCSisi Chen
Sisi Chen
RVRahul S. Vedula
Rahul S. Vedula
ACAntonio Cuevas-Navarro
Antonio Cuevas-Navarro
BLBin Lu
Bin Lu
SHSimon J. Hogg
Simon J. Hogg
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation

4 April 2023
Verified
Other
Open access
SCSisi Chen
Sisi Chen
RVRahul S. Vedula
Rahul S. Vedula
ACAntonio Cuevas-Navarro
Antonio Cuevas-Navarro
BLBin Lu
Bin Lu
SHSimon J. Hogg
Simon J. Hogg
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Recently, screens for mediators of resistance to FLT3 and ABL kinase inhibitors in leukemia resulted in the discovery of LZTR1 as an adapter of a Cullin-3 RING E3 ubiquitin ligase complex responsible for the degradation of RAS GTPases. In parallel, dysregulated LZTR1 expression via aberrant splicing and mutations was identified in clonal hematopoietic conditions. Here we identify that loss of LZTR1, or leukemia-associated mutants in the LZTR1 substrate and RAS GTPase RIT1 that escape degradation, drives hematopoietic stem cell (HSC) expansion and leukemia in vivo. Although RIT1 stabilization was sufficient to drive hematopoietic transformation, transformation mediated by LZTR1 loss required MRAS. Proteolysis targeting chimeras (PROTAC) against RAS or reduction of GTP-loaded RAS overcomes LZTR1 loss-mediated resistance to FLT3 inhibitors. These data reveal proteolysis of noncanonical RAS proteins as novel regulators of HSC self-renewal, define the function of RIT1 and LZTR1 mutations in leukemia, and identify means to overcome drug resistance due to LZTR1 downregulation.Significance:Here we identify that impairing proteolysis of the noncanonical RAS GTPases RIT1 and MRAS via LZTR1 downregulation or leukemia-associated mutations stabilizing RIT1 enhances MAP kinase activation and drives leukemogenesis. Reducing the abundance of GTP-bound KRAS and NRAS overcomes the resistance to FLT3 kinase inhibitors associated with LZTR1 downregulation in leukemia.This article is highlighted in the In This Issue feature, p. 2221

4 April 2023
Verified
Other
Open access
SCSisi Chen
Sisi Chen
RVRahul S. Vedula
Rahul S. Vedula
ACAntonio Cuevas-Navarro
Antonio Cuevas-Navarro
BLBin Lu
Bin Lu
SHSimon J. Hogg
Simon J. Hogg
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation